Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer?

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.06.19
Views: 411
Rating:

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Prof Matthew Galsky talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the NILE trial.

He give a brief overview of the trial, and explains how it could define the new standard of care in this setting.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation